Apple rolls out a software update that enables a redesigned blood oxygen monitoring feature for its Watch Series 9, 10, and Ultra 2, circumventing the ITC ban
Apple will be rolling out a redesigned version of the feature to the Series 9, 10 and Ultra 2 today.
Context & Ripple Effects
Apple’s path to this update runs through the 2024 import restriction: it prepared to sell affected Watch models without blood-oxygen functionality, following plans to remove the feature from U.S. sales. A customs decision in the Masimo dispute had already indicated that changing the feature could offer a route around the remedy, as described in the earlier CBP finding on a modified Watch design.
The rollout matters because it applies that redesign route through software across several recent Watch generations, rather than limiting the issue to a single new hardware release.
First-order effects
- Owners of Watch Series 9, Series 10, and Ultra 2 can receive Apple’s redesigned blood-oxygen monitoring feature through the software update.
- Apple regains a health-feature differentiator on the named U.S. Watch models while operating around the ITC restriction.
Second-order effects
- The move tests whether software and product redesigns can preserve device functionality under an import remedy, making the technical boundaries of the redesigned feature consequential for the underlying dispute.
- Rival wearable makers and health-feature suppliers face renewed pressure to differentiate as Apple restores a capability that had been absent from affected sales.
Third-order effects
- If redesigns repeatedly resolve feature-specific trade restrictions, hardware competition will increasingly hinge on how quickly companies can separate protected implementations from customer-facing capabilities.
- The case points to a more iterative relationship between IP enforcement and connected-device software: remedies may constrain particular implementations without permanently freezing a product category’s feature set.
The trend: Wearable health competition is shifting toward software-defined features whose availability can change with IP, regulatory, and product-design constraints.